You have 4 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BrCa

Showing 26 - 50 of 916
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Columbus (Informational Intervention, Survey Administration)

Recruiting
  • BRCA1 Gene Mutation
  • BRCA2 Gene Mutation
  • Informational Intervention
  • Survey Administration
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 2, 2022

Hot Flashes, Menopause Surgical Trial in Jerusalem (Acupuncture, Acupuncture-Acupressure)

Not yet recruiting
  • Hot Flashes
  • Menopause Surgical
  • Acupuncture
  • Acupuncture-Acupressure
  • Jerusalem, Israel
    Center for Integrative Complementary Medicine, Shaare Zedek Medi
Oct 24, 2022

Breast Cancer BRCA1 Carriers: a Pilot Study

Withdrawn
  • BRCA1 Mutation
  • +2 more
  • Mifepristone 200 MG
  • Prophylactic mastectomy
  • Carmel, Indiana
  • +1 more
Dec 13, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Adavosertib)

Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Jun 28, 2022

Metastatic or Unresectable Melanoma Trial in Cleveland (Nivolumab, Talazoparib)

Recruiting
  • Metastatic or Unresectable Melanoma
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
Mar 22, 2022

Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or

Recruiting
  • Ovarian Cancer
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Jul 13, 2022

    Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt

    Not yet recruiting
    • Advanced Ovarian Cancer
    • None (Observational Study)
    • (no location specified)
    Mar 8, 2023

    Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2

    Recruiting
    • Hereditary Breast and Ovarian Cancer
      • Barcelona, Spain
        Hospital de la Santa Creu i Sant Pau
      Jun 3, 2022

      BRCA1 Mutation, BRCA2 Mutation Trial in New York, Durham, Houston (Family Letter (Standard of Care), Educational Video, Mailed

      Recruiting
      • BRCA1 Mutation
      • BRCA2 Mutation
      • Family Letter (Standard of Care)
      • +3 more
      • New York, New York
      • +2 more
      Aug 12, 2022

      TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation Trial (olaparib, Durvalumab)

      Not yet recruiting
      • TNBC - Triple-Negative Breast Cancer
      • +2 more
      • (no location specified)
      Jan 12, 2022

      BRCA Founder OutReach (BFOR) Study

      Active, not recruiting
      • BRCA1 Mutation
      • BRCA2 Mutation
      • BFOR Digital Health solution/Web Portal
      • Los Angeles, California
      • +4 more
      May 11, 2022

      Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation Trial (Olaparib, LHRH agonist)

      Not yet recruiting
      • Prostate Cancer
      • +4 more
      • (no location specified)
      Aug 10, 2022

      Advanced Malignant Tumor, ATM Gene Mutation, BRCA1 Gene Mutation Trial in Houston (Laboratory Biomarker Analysis,

      Active, not recruiting
      • Advanced Malignant Neoplasm
      • +7 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Feb 21, 2022

      Breast Cancer Trial in Spain (Olaparib)

      Terminated
      • Breast Cancer
      • Barcelona, Spain
      • +7 more
      Jan 18, 2023

      Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer Trial in Birmingham (Cohort 1: Dose Escalation, Cohort 2: Dose

      Terminated
      • Ovarian Cancer
      • Resistant BRCA Wild-Type Ovarian Cancer
      • Cohort 1: Dose Escalation
      • Cohort 2: Dose Escalation
      • Birmingham, Alabama
        University of Alabama at Birmingham
      Apr 29, 2022

      Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by

      Completed
      • Breast Cancer
      • Blood test
      • Questionnaire
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      Dec 27, 2021

      An Imaging Study of FCH-PET-CT in Prostate Cancer andBRCA Gene

      Recruiting
      • Prostate Cancer
      • +2 more
      • MRI pelvis or CT imaging
      • +2 more
      • London, Sutton, Surrey, United Kingdom
        Cancer Genetics Unit, Royal Marsden Hospital
      Mar 30, 2022

      Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)

      Active, not recruiting
      • Advanced Breast Cancer
      • +2 more
      • Talazoparib Tosylate
      • Stanford, California
        Stanford University Hospitals and Clinics
      Nov 16, 2022

      Breast Cancer Trial in Tucson, Albuquerque (Pegylated liposomal doxorubicin)

      Completed
      • Breast Cancer
      • Pegylated liposomal doxorubicin
      • Tucson, Arizona
      • +1 more
      Jan 9, 2023

      Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma Trial (Nab paclitaxel,

      Not yet recruiting
      • Pancreatic Acinar Cell Carcinoma
      • +6 more
      • Nab paclitaxel
      • +5 more
      • (no location specified)
      Oct 30, 2023

      Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation Trial in Boston, New York (Melphalan, BCNU, Vitamin B12B)

      Recruiting
      • Pancreatic Adenocarcinoma Metastatic
      • +14 more
      • Boston, Massachusetts
      • +1 more
      Dec 6, 2022

      Breast Cancer Trial in Boston, Cambridge (Sapacitabine, Olaparib)

      Active, not recruiting
      • Breast Cancer
      • Boston, Massachusetts
      • +1 more
      May 2, 2022

      Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

      Not yet recruiting
      • Platinum-Resistant Fallopian Tube Carcinoma
      • +5 more
      • Biopsy
      • +4 more
      • Duarte, California
        City of Hope Medical Center
      Jan 3, 2023

      LYNPARZA Breast Cancer in Adjuvant Setting Japan Post-Marketing

      Not yet recruiting
      • Breast Cancer
        • (no location specified)
        Jan 9, 2023

        l, Laboratory and Epidemiologic Characterization of Individuals

        Completed
        • Familial Ovarian Cancer
        • +3 more
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          Dec 31, 2022